New England Rare Reagents specializes in the generation of antibodies, antigens and peptides for diagnostic or therapeutic use. New England Rare Reagents in Gorham is developing monoclonal antibody reagents that will recognize the B-amyloid protofibrils thought responsible for Alzheimers disease as well as for prions thought responsible for diseases such as Mad Cow and Chroning Wasting Disease. The management team includes Mark Donovan, CEO, formerly the Northeast Regional Sales Manager for Idexx Laboratories; Dr. Trebor Lawton, chief scientific officer, formerly a senior scientist at Idexx Laboratories and research fellow in medicine at the Harvard Medical School; and Barbara Bartol, senior scientist and chief technical officer, whose experience includes work for Ventrex Laboratories, Idexx Laboratories and Binax, Inc. NERR was recently awarded a seed grant by the Maine Technology Institute.
